Engineered immune cells take on lupus kidney disease in early trial
Disease control
Not yet recruiting
This early-phase study tests a new treatment called C-CAR168 for people with lupus nephritis that hasn't improved with standard therapies. C-CAR168 is made from a patient's own immune cells, which are modified to target and attack faulty immune cells. The study will enroll 24 adu…
Phase: PHASE1, PHASE2 • Sponsor: AbelZeta Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC